ENSC Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 2.80%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Ensysce Biosciences Insider Trading History Chart

Ensysce Biosciences Share Price & Price History

^$1.13

▼ -0.05 (-4.24%)

As of 12/17/2025 04:59 PM ET

Days: 30 | 90 | 365

Ensysce Biosciences Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/2/2023	Bob G Gower	Director	Buy	501	$88.20	$44,188.20	6,792

SEC Filings (Institutional Ownership Changes) for Ensysce Biosciences (NASDAQ:ENSC)

5.63% of Ensysce Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Ensysce Biosciences Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/17/2025	Citadel Advisors LLC	14,518	$34K	0.0%	N/A	0.489%
11/14/2025	Virtu Financial LLC	14,222	$34K	0.0%	N/A	0.479%
10/22/2025	TRU Independence Asset Management 2 LLC	10,500	$25K	0.0%	N/A	0.354%
5/16/2025	Murchinson Ltd.	140,000	$0.36M	0.0%	N/A	5.905%
5/16/2025	Adage Capital Partners GP L.L.C.	74,711	$0.19M	0.0%	+49.4%	3.151%
2/14/2025	Adage Capital Partners GP L.L.C.	50,000	$0.41M	0.0%	N/A	3.817%
11/15/2024	Anson Funds Management LP	983,518	$0.24M	0.0%	N/A	11.151%
11/15/2023	Sabby Management LLC	96,973	$0.13M	0.1%	-69.9%	3.079%
8/14/2023	Anson Funds Management LP	36,261	$65K	0.0%	N/A	2.833%
5/1/2023	Virtu Financial LLC	13,433	$65K	0.0%	N/A	1.049%

Data available starting January 2016

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

Today's Range

Now: $1.13

$1.11

$1.19

50 Day Range

MA: $1.95

$1.18

$2.57

52 Week Range

Now: $1.13

$1.11

$10.96

Volume

148,275 shs

Average Volume

608,418 shs

Market Capitalization

$4.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.15

Who are the major institutional investors of Ensysce Biosciences?: Ensysce Biosciences' top institutional shareholders include:
Citadel Advisors LLC — 0.49%
Virtu Financial LLC — 0.48%
TRU Independence Asset Management 2 LLC — 0.35%
Learn More about top institutional investors of Ensysce Biosciences stock.
Which institutional investors are buying Ensysce Biosciences stock?: During the last quarter, ENSC stock was acquired by institutional investors including:
Citadel Advisors LLC
Virtu Financial LLC
TRU Independence Asset Management 2 LLC